Our initial product candidate, CYN-102, is designed by engineering a Sindbis vector with a tumor-associated antigen (TAA) NY-ESO-1.

The potential of CYN-102 as an immunotherapy will be evaluated in clinical studies in ovarian cancer patients. Ovarian cancer is the 5th leading cause of cancer death among woman. The overall prevalence of Ovarian Cancer in the U.S. was 200,000+ patients; and estimated in 2016 there were 22,280 new cases and 14,240 deaths.

In addition, the Company is exploring the potential of Sindbis vectors and CYN-102 for the treatment of a wide range of cancers in various pre-clinical models. Furthermore, encouraging data has been obtained in combination studies with other new immunotherapeutic agents.